-
公开(公告)号：EP3299369B1
公开(公告)日：2020-11-11
申请号：EP16795921.2
申请日：2016-05-23
发明人： LONG, Yaqiu , GENG, Meiyu , XU, Zhongliang , AI, Jing
IPC分类号： C07D471/04 , A61K31/4375 , A61K31/5377 , A61K31/4545 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/501 , A61P35/00
-
2.发明公开
公开(公告)号：EP3584239A1
公开(公告)日：2019-12-25
申请号：EP18753647.9
申请日：2018-02-12
发明人： HU, Youhong , GENG, Meiyu , REN, Wenming , DING, Jian , GUAN, Xiaocong , AI, Jing , WANG, Lang , PENG, Xia , LIU, Yang , DAI, Yang , ZENG, Limin
IPC分类号： C07D213/73 , C07D213/75 , C07D241/20 , A61K31/4965 , A61K31/44 , A61P35/00
摘要： An o -aminoheteroaryl alkynyl-containing compound, a preparation method therefor and a use thereof. The o -aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data has showed that the o -aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.
-
公开(公告)号：EP3470415A1
公开(公告)日：2019-04-17
申请号：EP17802189.5
申请日：2017-05-24
发明人： JIANG, Hualiang , LIU, Hong , GENG, Meiyu , ZHENG, Mingyue , AI, Jing , WANG, Yulan , WU, Xiaowei , LI, Shuangjie , PENG, Xia , LI, Chunpu , CHEN, Kaixian , WANG, Bao
IPC分类号： C07D487/04 , A61K31/5025 , A61K31/5377 , A61K31/541
摘要： The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.
-
公开(公告)号：EP4296266A1
公开(公告)日：2023-12-27
申请号：EP22755576.0
申请日：2022-02-18
发明人： HU, Youhong , GENG, Meiyu , LI, Daqiang , SHEN, Aijun , ZHANG, Zhuo , LI, Yalei , YANG, Huajie , LIU, Hongchun , ZHONG, Hanyue , DING, Jian
IPC分类号： C07D237/14 , C07D401/04 , C07D403/04 , A61K31/50 , A61K31/501 , A61P3/10 , A61P25/00 , A61P25/28 , A61P29/00 , A61P33/06 , A61P35/00
摘要： The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to a compound represented by the following general formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition and application thereof. The S-configuration compound of the present application has very strong binding activity on class I histone deacetylase (HDAC1), and shows inhibitory activity on in-vitro proliferation of various tumor cells.
-
公开(公告)号：EP3815692A1
公开(公告)日：2021-05-05
申请号：EP19825647.1
申请日：2019-06-28
申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： GENG, Meiyu , ZHANG, Zhenqing , JIN, Yingshen , XIAO, Zhongping , DING, Jian
摘要： The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m' is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.
-
公开(公告)号：EP3778585A1
公开(公告)日：2021-02-17
申请号：EP19777026.6
申请日：2019-03-29
申请人： Haihe Biopharma Co., Ltd. , Jinan University , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： DING, Ke , GENG, Meiyu , CHAN, Shingpan , DING, Jian , TAN, Li , AI, Jing , ZHANG, Zhang , PENG, Xia , REN, Xiaomei , JI, Yinchun , TU, Zhengchao , DAI, Yang , LU, Xiaoyun
IPC分类号： C07D401/12 , C07D403/12 , C07D215/233 , A61K31/4709 , A61P35/00
摘要： The present invention relates to quinoline or quinazoline compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a prodrug molecule thereof, or a deuterated compound thereof. The compound of the present invention is effective in inhibiting the action of AXL protein kinase and can inhibit proliferation, migration, and invasion of various tumor cells. Further, the quinoline or quinazoline compound of the present invention has excellent metabolic stability, high in vivo antitumor activity, low toxic side effects, and can be used for preparing a drug for preventing hyperproliferative diseases such as tumors in humans and other mammals.
-
7.发明授权
公开(公告)号：EP3546460B1
公开(公告)日：2020-07-08
申请号：EP17874613.7
申请日：2017-11-24
发明人： ZHANG, Ao , DING, Jian , XIE, Hua , SONG, Zilan , XUE, Yu , TONG, Linjiang , GENG, Meiyu
IPC分类号： C07D471/14 , C07D487/14 , A61K31/519 , A61P35/00 , A61P35/02 , A61P29/00 , A61P37/02
-
公开(公告)号：EP2917210B1
公开(公告)日：2019-02-27
申请号：EP13853072.0
申请日：2013-11-05
申请人： Shanghai Fochon Pharmaceutical Co. Ltd , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： WANG, Weibo , GENG, Meiyu , DING, Jian , ZHAO, Xingdong , AI, Jing , TIAN, Qiang , PENG, Xia , ZHANG, Weipeng , LIU, Hongbin , TAN, Haohan , CHEN, Ling
IPC分类号： C07D405/14 , A61K31/558 , A61P35/00
-
9.发明公开
公开(公告)号：EP3418277A1
公开(公告)日：2018-12-26
申请号：EP17752701.7
申请日：2017-02-17
发明人： ZHANG, Ao , GENG, Meiyu , XING, Li , AI, Jing , SONG, Zilan , PENG, Xia , GU, Wangting , DING, Jian
IPC分类号： C07D401/12 , C07D213/75 , C07D413/12 , C07D417/12 , C07D403/12 , C07D405/12 , A61K31/4427 , A61K31/44 , A61K31/4439 , A61K31/4545 , A61P35/00
CPC分类号： A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4545 , C07D213/75 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.
-
公开(公告)号：EP4219456A1
公开(公告)日：2023-08-02
申请号：EP21871504.3
申请日：2021-09-22
发明人： DING, Jian , DUAN, Wenhu , XIE, Hua , GENG, Meiyu , WANG, Caixia , ZHAN, Zhengsheng , GAO, Na , ZHANG, Yang
IPC分类号： C07D231/56 , A61K31/416 , A61P35/00
摘要： Provided is the use of a CSF1R kinase inhibitor compound or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating diseases related to the CSF1R kinase signal transduction pathway or drugs for regulating immunization.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.023 秒)
